| Literature DB >> 28752392 |
Walid Sabri Hamadou1, Rahma Mani2, Sawsen Besbes2, Violaine Bourdon3, Yosra Ben Youssef2,4, François Eisinger5, Véronique Mari6, Paul Gesta7, Hélène Dreyfus8, Valérie Bonadona9, Catherine Dugast10, Hélène Zattara11, Laurence Faivre12, Testsuro Noguchi3, Abderrahim Khélif2,4, Hagay Sobol3, Zohra Soua2.
Abstract
The genetic predisposition to familial hematological malignancies has been previously reported highlighting inherited gene mutations. Several genes have been reported but genetic basis remains not well defined. In this study, we extended our investigation to a potential candidate GATA2 gene which was analyzed by direct sequencing in 119 cases including familial aggregations with a variety of hematological malignancies and sporadic acute leukemia belonging to Tunisian and French populations. We reported a deleterious p.Arg396Gln GATA2 mutation in one patient diagnosed with both sporadic acute myeloid leukemia (AML) and breast cancer. We also reported several GATA2 variations in familial cases. The absence of deleterious mutations in this large cohort of familial aggregations of hematological malignancies may strengthen the hypothesis that GATA2 mutations are an important predisposing factor, although as a secondary genetic event, required for the development of overt malignant disease.Entities:
Keywords: Familial hematological malignancies; GATA2 gene; Gene mutations; Sporadic acute leukemia
Mesh:
Substances:
Year: 2017 PMID: 28752392 DOI: 10.1007/s00277-017-3076-9
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673